Table 1. Post-progression anticancer treatments.

Types of post-progression anticancer treatment	Total patients (n=60) (%)
Salvage chemotherapy	42 (70.0)
Platinum-based chemotherapy*	31 out of 42 (73.8)
Mono-chemotherapy**	11 out of 42 (26.2)
Pembrolizumab beyond progression	18 (30.0)

*, n=12 carboplatin/pemetrexed; n=5 carboplatin/gemcitabine; n=4 cisplatin/pemetrexed; n=3 carboplatin/paclitaxel; n=3 carboplatin/nab-paclitaxel; n=2 carboplatin/paclitaxel/bevacizumab; n=1 cisplatin/gemcitabine; n=1 carboplatin. **, n=7 gemcitabine; N=4 docetaxel.